ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-26 pm EST 5-day change 1st Jan Change
318.7 USD +1.44% Intraday chart for ICON Public Limited Company +10.28% +12.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Evercore ISI Adjusts Price Target on ICON to $350 From $325, Keeps Outperform Rating MT
UBS Adjusts ICON Price Target to $368 From $295, Maintains Buy Rating MT
Mizuho Securities Ups Price Target on ICON to $346 From $315, Keeps Buy Rating MT
Barclays Adjusts Price Target on ICON to $355 From $325, Maintains Overweight Rating MT
Truist Securities Raises Price Target on ICON to $367 From $357, Maintains Buy Rating MT
ICON Shares Rise After Q4 Results, Guidance Reaffirmed MT
Deutsche Bank Raises ICON Price Target to $345 From $320, Maintains Buy Rating MT
ICON Seeks M&A CI
Transcript : ICON Public Limited Company, Q4 2023 Earnings Call, Feb 22, 2024
ICON Q4 Adjusted Earnings, Revenue Increase; 2024 Guidance Affirmed MT
ICON Public Limited Company announces an Equity Buyback for $500 million worth of its shares. CI
Earnings Flash (ICLR) ICON Posts Q4 Revenue $2.07B, vs. Street Est of $2.09B MT
Earnings Flash (ICLR) ICON Reports Q4 EPS $3.46, vs. Street Est of $3.45 MT
ICON Public Limited Company Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024 CI
ICON Public Limited Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
The fate of the market depends on this Our Logo
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
ICON Public Limited Company authorizes a Buyback Plan. CI
Barclays Adjusts Price Target on ICON to $325 From $280, Maintains Overweight Rating MT
Transcript : ICON Public Limited Company Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM
ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024 CI
Slow start for Wall Street Our Logo
Analyst recommendations: Blackstone, Citigroup, Icon, Amazon, Broadcom... Our Logo
Truist Securities Starts Coverage on ICON with Buy Rating, $357 Price Target MT
Chart ICON Public Limited Company
More charts
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors. Its sectors include Biosimilars, Biotech, Government and public health solutions, medical devices, pharmaceuticals and the IVDR journey.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
318.7 USD
Average target price
350.6 USD
Spread / Average Target
+9.99%
Consensus
  1. Stock
  2. Equities
  3. Stock ICON Public Limited Company - Nasdaq
  4. News ICON Public Limited Company
  5. Baird Adjusts Price Target on ICON to $287 From $278, Keeps Outperform Rating
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW